Apremilast in the Treatment of Uveitis

• Status: Terminated
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and efficacy of Apremilast in the treatment of uveitis.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborator: Celgene Corporation
• Treatments: Apremilast; Thalidomide

Criteria

Inclusion Criteria:

• patients with vision-threatening autoimmune uveitis

• failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects

Exclusion Criteria:

• serious concomitant illness that could interfere with the subject's participation

• previous or current use of an alkylating agent

• use of CYP3A4 inhibitors during the trial

• TNF blocker use within the 8 weeks prior to enrollment